Evidence map›Paper›PMID 31907866›Full record

ArticleJournal of molecular neuroscience : MN2020

Phenotypic Differences in Primary Murine Microglia Treated with NOD1, NOD2, and NOD1/2 Agonists.

Susanne Wasmuth, Tida Viola Jalilvand, Björn Laffer, Martin Busch, Dirk Bauer, Thomas Langmann, Solon Thanos, Maren Kasper, Arnd Heiligenhaus

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Susanne WasmuthOphtha-Lab, Ophthalmic Center at St.Franziskus Hospital, Münster, Germany.ORCID http://orcid.org/0000-0003-1422-9642
Tida Viola JalilvandOphtha-Lab, Ophthalmic Center at St.Franziskus Hospital, Münster, Germany.
Björn LafferOphtha-Lab, Ophthalmic Center at St.Franziskus Hospital, Münster, Germany.
Martin BuschOphtha-Lab, Ophthalmic Center at St.Franziskus Hospital, Münster, Germany.ORCID http://orcid.org/0000-0001-6259-3946
Dirk BauerOphtha-Lab, Ophthalmic Center at St.Franziskus Hospital, Münster, Germany.ORCID http://orcid.org/0000-0002-3647-2777
Thomas LangmannLaboratory for Experimental Immunology of the Eye, Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0001-6826-529X
Solon ThanosDepartment of Experimental Ophthalmology, Westphalian Wilhelms University of Münster, Münster, Germany.
Maren KasperOphtha-Lab, Ophthalmic Center at St.Franziskus Hospital, Münster, Germany.ORCID http://orcid.org/0000-0003-2964-8866
Arnd HeiligenhausOphtha-Lab, Ophthalmic Center at St.Franziskus Hospital, Münster, Germany. arnd.heiligenhaus@uveitis-zentrum.de.ORCID http://orcid.org/0000-0002-1726-8973
St. Franziskus Hospital · DEUniversity of Münster · DEUniversity of Cologne · DE

Funding

DFG FOR 2240 (Lymph)angiogenesis and cellular immunity in inflammatory diseases of the eye
6 · The paper itself

Abstract

The purpose of the study was studying the influence of different NOD agonists on the morphological phenotype of primary murine microglia and to examine their influence on characteristic cytokines. Primary CD11b-positive cells were isolated from the brain of neonatal mice. The microglial phenotype of the cells was examined by ionized calcium-binding adapter molecule (Iba)1 staining. After14 days in culture, these cells were stimulated by iE-DAP, L18-MDP, or M-TriDAP as NOD1, NOD2, and NOD1/2 agonists, respectively. The cellular morphology was recorded and compared to the phenotype of cells cultured in medium alone or after LPS stimulation. The cells developed a specific phenotype only after treatment with the NOD2 agonist L18-MDP. These cells were characterized by straight extensions carrying tiny spikes and had a high ramification index. This was in sharp contrast to all other treatments, which always resulted in an amoeboid phenotype typically shown by activated microglia in vivo and by cultured microglia in vitro. The staining intensity of IL-6 and TNF-α did not reveal any clear difference independent of the NOD agonist treatment. In contrast, an increased staining intensity was observed for IL-10 after L18-MDP treatment. The NOD2 agonist L18-MDP induced a morphologically distinct phenotype characterized by microspike-decorated dendritiform extensions and a high degree of ramification in primary murine microglia. Increased ramification index and elevated staining intensity of anti-inflammatory IL-10 as hallmarks suggest that a M2-like phenotype of microglia was induced.

Indexed as

PhenotypeAcetylmuramyl-Alanyl-IsoglutamineAdjuvants, ImmunologicAnimalsCalcium-Binding ProteinsCells, CulturedCell ShapeCell Surface ExtensionsDiaminopimelic AcidInterleukin-6MiceMice, Inbred C57BLMicrofilament ProteinsMicrogliaNod1 Signaling Adaptor ProteinNod2 Signaling Adaptor ProteinAcetylmuramyl-Alanyl-IsoglutamineAdjuvants, ImmunologicAif1 protein, mouseCalcium-Binding ProteinsDiaminopimelic AcidInterleukin-6Microfilament ProteinsN(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acidNod1 protein, mouseNod1 Signaling Adaptor ProteinNod2 protein, mouseNod2 Signaling Adaptor ProteinTumor Necrosis Factor-alphaIn vitro studyMicrogliaNOD1/2 agonistsPhenotype

Identifiers

PMID31907866
OpenAlexW3000073272

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.